Hepatitis C Treatment Naive Genotype 1 Consensus Interferon Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

July 31, 2008

Study Completion Date

September 30, 2009

Conditions
Chronic Hepatitis C
Interventions
DRUG

consensus interferon (Interferon Alfacon-1) and ribavirin

CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)

DRUG

Consensus Interferon alfa (CIFN) and ribavirin

CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Center for Veterans Research and Education

OTHER

collaborator

InterMune

INDUSTRY

collaborator

Kadmon Corporation, LLC

INDUSTRY

collaborator

US Department of Veterans Affairs

FED

collaborator

San Diego Veterans Healthcare System

FED

lead

Minneapolis Veterans Affairs Medical Center

FED

NCT00211692 - Hepatitis C Treatment Naive Genotype 1 Consensus Interferon Trial | Biotech Hunter | Biotech Hunter